Company / Gross Profit
UroGen Pharma Ltd. Gross Profit History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit
$97.3M
FY2025
5-year range
$33.6M / $97.3M
FY2021-FY2025
Trend
+189.5%
vs FY2024
Sector context
#26 of 29
Health Care
What the data says
Among 29 Health Care companies, UroGen Pharma Ltd. is in the bottom 10% for gross profit. Gross Profit has fluctuated over the past 10 years, ranging from -$675,000 in FY2018 to $97M in FY2025.
Based on SEC 10-K filings.
$97M in FY2025 with a 5-year CAGR of +458.0%.
Improved from $57M to $97M over the past 2 years.
Health Care sector context is included.
Gross Profit over time
Growth rates
- 3-Year CAGR
- +31.4%
- 5-Year CAGR
- +458.0%
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 29This company $97.3M Sector average $3.5B
▼
-97.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +458.0%, indicating consistent growth.
- In FY2025, gross profit increased 189.5% year-over-year.
- Ranks #26 out of 29 companies in the Health Care sector.
- Lowest gross profit in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.09 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross ProfitValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $97.3M | +189.5% |
| FY2024 | $33.6M | -40.7% |
| FY2023 | $56.7M | +32.2% |
| FY2022 | $42.9M | +0.0% |
| FY2021 | $42.9M | +238150.0% |
| FY2020 | $18.0K | -99.8% |
| FY2019 | $7.6M | +1219.7% |
| FY2018 | -$675.0K | -108.9% |
| FY2017 | $7.6M | -56.8% |
| FY2016 | $17.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026